Prevalence of Risk Determinants for Metformin-associated Lactic Acidosis and Metformin Utilization in the Study of Health in Pomerania

Abstract

Risk determinants for the life threatening complication of metformin-associated lactic acidosis are frequently disregarded. Our first aim was to investigate the prevalence of risk determinants in subjects with type 2 diabetes mellitus (DM2) taking metformin compared to subjects with nonmetformin treatment. Our second aim was to estimate the proportion of subjects with alternative drug-treatment, and no risk determinants, which would probably benefit from metformin. The Study of Health in Pomerania is a population-based health survey including 322 DM2 subjects. Risk determinants were assessed by personal interview, ultrasound, and laboratory analysis. Among the subjects with DM2 n=92 (28.6%) were treated with metformin, n=162 (50.3%) with alternative medication, and n=68 (21.1%) with diet. The prevalence of at least one risk determinant was 62% for metformin-users. There was no difference in number and type of risk determinants. Heart failure, angina pectoris, and liver disorders presented the most frequent risk determinants. Current risk determinants for metformin-associated lactic acidosis are largely disregarded. Improved selection of patients can result in safe metformin utilization in one quarter of subjects on DM2 related drug treatment. Risk determinants need to be revised. A more practical definition of risk determinants would improve prescription adherence.

metformin - lactic acidosis - prevalence

References

• 1 UKPDS Group . Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.  Lancet. 1998;  352 854-865
• 2 Jones GC, Macklin JP, Alexander WD. Contraindications to the use of metformin.  BMJ. 2003;  326 4-5
• 3 Fantus IG. Metformin's contraindications: needed for now.  CMAJ. 2005;  173 505-507
• 4 Kirpichnikov D, MacFarlane SI, Sowers JR. Metformin: an update.  Ann Intern Med. 2002;  137 25-33
• 5 Holstein A, Stumvoll M. Contraindications can damage your health–is metformin a case in point?.  Diabetologia. 2005;  48 2454-2459
• 6 Runge S, Mayerle J, Warnke C. et al . Metformin-associated lactic acidosis in patients with renal impairment solely due to drug accumulation?.  Diabetes Obes Metab. 2008;  10 91-93
• 7 Sulkin TV, Bosman D, Krentz AJ. Contraindications to metformin therapy in patients with NIDDM.  Diabetes Care. 1997;  20 925-928
• 8 Horlen C, Malone R, Bryant B. et al . Frequency of inappropriate metformin prescriptions.  JAMA. 2002;  287 2504-2505
• 9 Cohen RD, Woods HF. Metformin and lactic acidosis.  Diabetes Care. 1999;  22 1010-1011
• 10 Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis.  Arch Intern Med. 2003;  163 2594-2602
• 11 Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.  Cochrane database of systematic reviews (Online). 2006;  CD002967
• 12 Stang M, Wysowski DK, Butler-Jones D. Incidence of lactic acidosis in metformin users.  Diabetes Care. 1999;  22 925-927
• 13 Emslie-Smith AM, Boyle DI, Evans JM, Sullivan F, Morris AD. Contraindications to metformin therapy in patients with type 2 diabetes–a population-based study of adherence to prescribing guidelines.  Diabet Med. 2001;  18 483-488
• 14 Holstein A, Nahrwold D, Hinze S, Egberts EH. Contra-indications to metformin therapy are largely disregarded.  Diabet Med. 1999;  16 692-696
• 15 MacCormack J, Johns K, Tildesley H. Metformin's contraindications should be contraindicated.  CMAJ. 2005;  173 502-504
• 16 Tahrani A, Varughese G, Scarpello J, Hanna F. Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated?.  BMJ. 2007;  335 508-512
• 17 John U, Greiner B, Hensel E. et al . Study of Health In Pomerania (SHIP): a health examination survey in an east German region: objectives and design.  Soz Praventivmed. 2001;  46 186-194
• 18 Schiller NB, Shah PM, Crawford M. et al . Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms.  J Am Soc Echocardiogr. 1989;  2 358-367
• 19 Köhler E. Ein- und zweidimensionale Echokardiografie mit Dopplertechnik. Stuttgart: Ferdinand Enke Verlag 1992
• 20 Miller-Davis C, Marden S, Leidy NK. The New York Heart Association Classes and functional status: what are we really measuring?.  Heart Lung. 2006;  35 217-224
• 21 Rose GA, Blackburn H, Gillum RF, Prineas RJ. Cardiovascular survey methods. 2 ed. Geneva: WHO 1982
• 22 Alte D, Luedemann J, Rose HJ, John U. Laboratory markers carbohydrate-deficient transferrin, gamma-glutamyltransferase, and mean corpuscular volume are not useful as screening tools for high-risk drinking in the general population: results from the Study of Health in Pomerania (SHIP).  Alcohol Clin Exp Res. 2004;  28 931-940
• 23 Alte D, Lüdemann J, Piek M. et al . Distribution and dose response of laboratory markers to alcohol consumption in a general population: results of the study of health in Pomerania (SHIP).  J Stud Alcohol. 2003;  64 75-82
• 24 Völzke H, Robinson DM, Schminke U. et al . Thyroid function and carotid wall thickness.  The Journal of clinical endocrinology and metabolism. 2004;  89 2145-2149
• 25 Calabrese AT, Coley KC, DaPos SV, Swanson D, Rao RH. Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy.  Arch Intern Med. 2002;  162 434-437
• 26 Rakovac I, Jeitler K, Gfrerer RJ. et al . Patients with type 2 diabetes treated with metformin: prevalence of contraindications and their correlation with discontinuation.  Diabet Med. 2005;  22 662-664
• 27 Kennedy L, Herman WH. Renal status among patients using metformin in a primary care setting.  Diabetes Care. 2005;  28 922-924
• 28 Misbin RI. The phantom of lactic acidosis due to metformin in patients with diabetes.  Diabetes Care. 2004;  27 1791-1793
• 29 Eurich DT, Majumdar SR, MacAlister FA, Tsuyuki RT, Johnson JA. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure.  Diabetes Care. 2005;  28 2345-2351
• 30 Wysowski DK, Armstrong G, Governale L. Rapid increase in the use of oral antidiabetic drugs in the United States, 1990–2001.  Diabetes Care. 2003;  26 1852-1855
• 31 Fischbacher CM, Bhopal R, Unwin N, White M, Alberti KG. The performance of the Rose angina questionnaire in South Asian and European origin populations: a comparative study in Newcastle, UK.  Int J Epidemiol. 2001;  30 1009-1016

1 These authors contributed equally to this manuscript.

Correspondence